for people with a very tough blood cancer (aml) that keeps coming back, early data on a drug called annamycin is really encouraging. 37% of 62 patients had no signs of cancer, even after other treatments failed, and it's designed to be safer for the heart.
Moleculin Biotech's Annamycin Shows 37% Complete Remission Rate in Latest Blinded Analysis for RelapMoleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin combined with cytarabine in patients with relapsed or refractory acute www.stocktitan.net